title: Aerobic exercise and intraocular pressure in normotensive and glaucoma patients.
abstract: BACKGROUND
  With the increasing number of people participating in physical aerobic exercise, jogging in particular, we considered that it would be worth knowing if there are should be limits to the exercise with regard to the intraocular pressure (IOP) of the eyes. The purpose of this study is to check IOP in healthy and primary glaucoma patients after aerobic exercise.
  
  
  METHODS
  145 individuals were subdivided into seven groups: normotensives who exercised regularly (Group A); normotensives in whose right eye (RE) timolol maleate 0.5% (Group B), latanoprost 0.005% (Group C), or brimonidine tartrate 0.2% (Group D) was instilled; and primary glaucoma patients under monotherapy with beta-blockers (Group E), prostaglandin analogues (Group F) or combined antiglaucoma treatment (Group G) instilled in both eyes. The IOP of both eyes was measured before and after exercise.
  
  
  RESULTS
  A statistically significant decrease was found in IOP during jogging. The aerobic exercise reduces the IOP in those eyes where a b-blocker, a prostaglandin analogue or an alpha-agonist was previously instilled. The IOP is also decreased in glaucoma patients who are already under antiglaucoma treatment.
  
  
  CONCLUSIONS
  There is no ocular restriction for simple glaucoma patients in performing aerobic physical activity.
authors.affiliation: Department of Anatomy, Medical School, Aristotle University of Thessaloniki, Greece. natsis@med.auth.gr
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Natsis
authors.forename: Irene
authors.initials: I
authors.lastname: Asouhidou
authors.forename: George
authors.initials: G
authors.lastname: Nousios
authors.forename: Theodosios
authors.initials: T
authors.lastname: Chatzibalis
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Vlasis
authors.forename: Vasilios
authors.initials: V
authors.lastname: Karabatakis
mesh_terms: D000293:Adolescent; D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage; D000068438:Brimonidine Tartrate; D015444:Exercise / Q000502:physiology*; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects / Q000502:physiology*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage; D011810:Quinoxalines / Q000008:administration & dosage; D013999:Timolol / Q000008:administration & dosage
chemical_list: D000316:Adrenergic alpha-Agonists; D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D011810:Quinoxalines; D000068438:Brimonidine Tartrate; D000077338:Latanoprost; D013999:Timolol
references.citation: Arch Ophthalmol. 1967 Jan;77(1):99-104
references.pmid: 4959319
references.citation: Am J Ophthalmol. 1970 Feb;69(2):245-8
references.pmid: 5414005
references.citation: Ophthalmology. 1992 Jul;99(7):1096-103
references.pmid: 1495789
references.citation: Eur J Appl Physiol Occup Physiol. 1983;52(1):136-8
references.pmid: 6686123
references.citation: Eur J Ophthalmol. 2004 Mar-Apr;14(2):117-22
references.pmid: 15134108
references.citation: Invest Ophthalmol. 1975 Oct;14(10):782-5
references.pmid: 241730
references.citation: Graefes Arch Clin Exp Ophthalmol. 1994 May;232(5):262-4
references.pmid: 8045434
references.citation: Am J Ophthalmol. 1967 Jun;63(6):1673-6
references.pmid: 6027342
references.citation: Invest Ophthalmol Vis Sci. 1992 Sep;33(10):2874-7
references.pmid: 1526737
references.citation: Eye (Lond). 1989;3 ( Pt 4):477-83
references.pmid: 2606224
references.citation: Lancet. 1947 Mar 29;1(6448):402-5
references.pmid: 20289886
references.citation: Eye (Lond). 2001 Oct;15(Pt 5):616-20
references.pmid: 11702973
references.citation: Invest Ophthalmol. 1974 Jan;13(1):74-6
references.pmid: 4809513
references.citation: Invest Ophthalmol Vis Sci. 1994 Oct;35(11):3852-7
references.pmid: 7928182
references.citation: Int Ophthalmol. 1995-1996;19(6):359-62
references.pmid: 8970870
references.citation: Arch Ophthalmol. 1991 Aug;109(8):1096-8
references.pmid: 1867551
references.citation: J Int Med Res. 2002 Jan-Feb;30(1):26-33
references.pmid: 11921496
references.citation: Acta Ophthalmol Scand. 2001 Dec;79(6):567-71
references.pmid: 11782220
references.citation: Invest Ophthalmol Vis Sci. 1999 Apr;40(5):1011-5
references.pmid: 10102302
references.citation: Br J Ophthalmol. 1978 Oct;62(10):679-81
references.pmid: 708668
references.citation: Jpn J Physiol. 1995;45(4):561-9
references.pmid: 7474535
references.citation: Ann Hum Biol. 1995 Nov-Dec;22(6):545-53
references.pmid: 8815781
references.citation: Int J Neurosci. 2006 Mar;116(3):351-60
references.pmid: 16484060